Implanet S.A (IMPZY) Fair Value & Analysis
Healthcare · US · Market cap $230M
Implanet S.A
IMPZY · US
Fair value as of: Jun 23, 2026
From 4 valuation models · updated 48 days ago
Below-average quality, and screening another 79% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.0170). The favourable scenario is already priced in.
- Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range ($0.0085 to $0.0170) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.
How to read this chart
60‑month range $0.0396 – $0.1039 · fair‑value band $0.0085 – $0.0170 · the $0.0800 price screens above the $0.0170 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jun 23, 2026.
Analysis
Implanet S.A (IMPZY) currently trades at $0.0800, while our model-based Fair Value estimate is $0.0170, implying the stock looks roughly 78.8% overvalued today. The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Implanet S.A generated revenue of $12.5M at a net margin of -35.1%. Revenue grew 26.0% year over year. Net debt stands at $2.9M. Fundamentals as of Jun 23, 2026
Our scenario range runs from $0.0085 (bear case) to $0.0170 (bull case); at $0.0800, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -79%, IMPZY screens richer than that median.
Notify me when IMPZY reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jun 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 33 · Market factors (momentum, volatility) 64
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Implanet S.A., together with its subsidiaries, manufactures and sells implants and medical instruments for orthopedic surgery in France, the United States, Europe, the Middle East, Africa, and internationally.
Full company description
Implanet S.A., together with its subsidiaries, manufactures and sells implants and medical instruments for orthopedic surgery in France, the United States, Europe, the Middle East, Africa, and internationally. The company offers spinal and knee products, including Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Olea, Saxxo, Swingo, Shark, Origin, and Jazz Frame, as well as ISS-Jazz Screw systems for posterior fixation. It also provides an ultrasonic osteotomy surgical system; and knee prostheses under the Madison name. The company exports its products. Implanet S.A. was founded in 2006 and is headquartered in Martillac, France.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Implanet S.A reported revenue of $12.5M in FY2025 versus $6.1M in FY2021, a compound +19.4%/yr. Reported net income was −$4.4M in FY2025.
IMPZY screens 79% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Implanet S.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Implanet S.A (IMPZY) overvalued or undervalued?
What is the fair value of IMPZY?
What is the quality score of IMPZY?
What is the revenue of Implanet S.A (IMPZY)?
What is the net profit margin of IMPZY?
Does Implanet S.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Implanet S.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.